Literature DB >> 17706322

Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey.

Elizabeth J Horn1, Kathleen M Fox, Vaishali Patel, Chiun-Fang Chiou, Frank Dann, Mark Lebwohl.   

Abstract

OBJECTIVE: We sought to assess whether patients with psoriasis with moderate or severe disease are being treated with systemic therapy.
METHODS: Participants were identified from a random sample of the National Psoriasis Foundation contact database who were 18 years and older, with severe psoriasis (>10% body surface area) and moderate psoriasis (3%-10% body surface area); respondents with psoriatic arthritis were excluded.
RESULTS: In all, 1657 respondents with psoriasis completed the survey (28% severe, 41% moderate). A total of 39% of respondents with severe psoriasis and 37% with moderate psoriasis were not currently receiving any treatment. Among respondents currently receiving therapy, only 43% of respondents with severe psoriasis received either traditional systemic therapy, biologic therapy, or phototherapy. LIMITATIONS: Respondents were from the National Psoriasis Foundation contact database and reported their current severity, which may be affected by their treatment. Body surface area as a measure of patient-reported severity has not been validated but has been used in several published studies.
CONCLUSIONS: Almost 40% of respondents with psoriasis were currently not receiving treatment. For respondents with severe psoriasis, 26% were treated with systemic therapy, phototherapy, or both; 39% were not in treatment; and 35% were treated with topical therapy alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706322     DOI: 10.1016/j.jaad.2007.06.042

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  25 in total

Review 1.  Diagnosis and management of psoriasis.

Authors:  Whan B Kim; Dana Jerome; Jensen Yeung
Journal:  Can Fam Physician       Date:  2017-04       Impact factor: 3.275

2.  Malaysian Clinical Practice Guideline for the Management of Psoriasis Vulgaris: Summary of recommendations for management in primary healthcare setting.

Authors:  Se Choon; Lc Chan; Siew Eng Choon; Adawiyah Jamil; Chan Lee Chin; Chong Hwee Cheng; Dawn Ambrose; Hazreen Abdul Majid; Koh Chang Heng; Loh Yet Lin; Mohd Aminuddin Mohd Yusof; Sin Lian Thye; Suganthi Thevarajah; Suriati Hashim; Tang Jyhe Jong; Wong Su Ming; Yunus Shariff
Journal:  Malays Fam Physician       Date:  2014-04-30

3.  Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015.

Authors:  Moa P Lee; Joyce Lii; Yinzhu Jin; Rishi J Desai; Daniel H Solomon; Joseph F Merola; Seoyoung C Kim
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-03-23       Impact factor: 4.794

4.  Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women.

Authors:  Shaowei Wu; Wen-Qing Li; Jiali Han; Qi Sun; Abrar A Qureshi
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

5.  Psoriasis and the risk of diabetes: A prospective population-based cohort study.

Authors:  Marilyn T Wan; Daniel B Shin; Rebecca A Hubbard; Megan H Noe; Nehal N Mehta; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-11-08       Impact factor: 11.527

Review 6.  The burden of moderate to severe psoriasis: an overview.

Authors:  Giovanna Raho; Daniela Mihajlova Koleva; Livio Garattini; Luigi Naldi
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

7.  Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

Authors:  Kim A Papp; James Signorovitch; Karthik Ramakrishnan; Andrew P Yu; Shiraz R Gupta; Yanjun Bao; Parvez M Mulani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

8.  Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Authors:  Howa Yeung; Joy Wan; Abby S Van Voorhees; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Daniel B Shin; Andrea B Troxel; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2012-07-28       Impact factor: 11.527

9.  The risk of stroke in patients with psoriasis.

Authors:  Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel
Journal:  J Invest Dermatol       Date:  2009-05-21       Impact factor: 8.551

10.  Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.

Authors:  Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-10       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.